Trending Topic

Breast Cancer
29 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Endocrine therapy (ET) has changed the natural history of hormone receptor-positive (HR+) breast cancer (BC) and is the cornerstone of the treatment of HR+ BC. There are several ETs approved for the treatment of BC, including selective oestrogen receptor modulators (SERMs; tamoxifen), aromatase inhibitors (AIs; anastrazole, letrozole and exemestane) and selective oestrogen receptor degraders (SERDs; fulvestrant […]

Mark Litzow, ASH 2022: Blinatumomab for BCR::ABL1 negative B-lineage acute lymphoblastic leukaemia, ECOG-ACRIN E1910 (a phase III study)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 21st 2022

The ECOG-ACRIN E1910 study assessed the benefit of blinatumomab for BCR::ABL1 negative B-lineage acute lymphoblastic leukaemia (ALL) patients who become measurable residual disease negative (<0.01%) after induction chemotherapy. In this touchONCOLOGY interview, we speak with Dr Mark Litzow (Mayo Clinic, Rochester, MN, USA) to discuss the findings of the study and their impact on the treatment paradigm for BCR::ABL1 negative ALL.

The abstract entitled ‘Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial’ (Abstract #LB-1) was presented at ASH Annual Meeting, 10–13, December, 2022.

Questions:

  1. What was the rationale for, and design of, the ECOG-ACRIN E1910 study? (0:22)
  2. What were the findings of the third interim efficacy analysis? (3:54)
  3. What will be the impact of these findings on the treatment paradigm for BCR::ABL1 negative ALL? (4:52)

Disclosures: Mark Litzow has received grant/research support from Amgen.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.

Filmed as a highlight of ASH 2022

Access more content on Haematological Malignancies and Leukaemia

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup